ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Congress Urges CMS To Soften Proposal For Coverage Of ESAs in Oncology.

July 20, 2007

ASCO Foundation Raised $200,000 In Its First Year.

June 2, 2000

Lederle Scientists Report Powerful New Anticancer Agent

July 31, 1987

More Shakeups Coming Cooperative groups; Chairmen Consider Mutimembership Problems

February 20, 1976

New England Medical Center Discloses Case Of Two Overdoses

April 28, 1995

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

April 16, 2004